NCCN updates guidelines recognizing MammaPrint to guide personalized anthracycline use in HR+/HER2- early‑stage breast cancer

Antibody halts triple-negative breast cancer in preclinical models

Triple-negative breast cancer is one of the most aggressive and treatment-resistant cancers. It grows quickly, spreads early, and lacks hormone receptors that make it treatable with targeted therapies. Even when patients initially respond to treatment, the cancer often returns and is more resistant.

January 30, 2026

Vol.52 No.04

By Hayley Kamin

Clinical Roundup

Oral bacterium may promote breast cancer development and spread, Hopkins study finds

Researchers at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy found that an oral bacterium commonly associated with periodontal disease can promote breast cancer initiation, tumor growth, and spread by inducing DNA damage and altering cancer cell behavior.

January 30, 2026

Vol.52 No.04

Drugs & Targets

Trodelvy added to NCCN guidelines as preferred regimen option for first-line metastatic TNBC

Trodelvy (sacituzumab govitecan-hziy) was added to the NCCN Guidelines as a category 1 preferred first-line treatment option for people with metastatic triple-negative breast cancer whose disease is PD-L1 negative (CPS <10) and no germline BRCA1/2 PV.

January 30, 2026

Vol.52 No.04

Clinical Roundup

Extracellular vesicles drug delivery mechanism could aid breast cancer treatment, UF study finds

Scientists from the UF Health Cancer Institute have found a way to make treatment for a notoriously aggressive breast cancer more effective.

January 23, 2026

Vol.52 No.03

Clinical Roundup

Researchers find cell markers to track TNBC, Baylor College of Medicine study finds

Of all the types of breast cancer, triple negative breast cancer is the most aggressive and lacks specific therapies. TNBC also is more likely to metastasize, or travel through the blood stream to spread to other organs, which causes most of breast cancer-related deaths each year.

January 23, 2026

Vol.52 No.03

Drugs & Targets

Personalis Real-Time Variant Tracker identifies resistance mutations across several hundred clinically relevant hotspots

Personalis announced the early access launch of Real-Time Variant Tracker, a powerful new option added to its ultrasensitive NeXT Personal molecular residual disease test designed to detect small traces of circulating tumor DNA in the blood that represent residual or recurrent cancer.

January 23, 2026

Vol.52 No.03

NCCN updates guidelines recognizing MammaPrint to guide personalized anthracycline use in HR+/HER2- early‑stage breast cancer

YOU MAY BE INTERESTED IN

Antibody halts triple-negative breast cancer in preclinical models

Oral bacterium may promote breast cancer development and spread, Hopkins study finds

Trodelvy added to NCCN guidelines as preferred regimen option for first-line metastatic TNBC

Extracellular vesicles drug delivery mechanism could aid breast cancer treatment, UF study finds

Researchers find cell markers to track TNBC, Baylor College of Medicine study finds

Personalis Real-Time Variant Tracker identifies resistance mutations across several hundred clinically relevant hotspots

Renew today!

Subscriber content

Never miss an issue!

Login